text:
My Registration
Socceroos News
Australian U23s
Young Socceroos U20s News
Joeys U17s News
In Camp
The Beautiful Game
A-League Connection
Socceroos Squad
Young Socceroos U20s
Joeys U17s
Australia U23 Fixtures
2015 Asian Cup
Corporate & Hospitality
Donate to the Pararoos
Hospitality Packages
My Account My Registration Sign Out
Verbeek selects 30-man squad for remaining qualifiers
Qantas Socceroos Head Coach Pim Verbeek has selected an extended 30-player squad for the upcoming 2010 FIFA World Cup™ Asian Qualifier Round 4 matches against Qatar, Bahrain and Japan in June.
Joining the Qantas Socceroos squad for the first time are Rhys Williams and Dario Vidosic, who have both been rewarded with selection following their outstanding form at their respective clubs.
20-year old Rhys Williams recently publically declared his desire to be selected for the Qantas Socceroos after previously representing the Welsh Youth National team on 10 occasions. Williams, was loaned out to English Championship Club Burnley by his club Middlesbrough for the past season and helped the Clarets to the Football League Championship play-offs.
After moving from the Queensland Roar to FC Nurnberg in 2007, Dario Vidosic has become a regular member of his club-s first team squad this season. Having been used mostly as a substitute, Vidosic has made 11 appearances and scored 3 goals and is currently involved in the club-s play-off matches against Energie Cottbus for promotion to the German Bundesliga.
Nick Carle, Brad Jones, Adrian Madaschi, Mark Milligan, Matthew Spiranovic and Shane Steffanuto all return to the Qantas Socceroos squad after various lengths of time out of selection.
In particular, this will be Adrian Madaschi-s first Qantas Socceroos Squad since 2004. Perth-born Madaschi made his senior international debut for the Qantas Socceroos in 2004 against New Zealand, at the OFC Nations Cup in Adelaide, which was part of the qualification process for the 2006 FIFA World Cup™. His last match for the Qantas Socceroos was against Fiji at the same tournament. Currently playing in the Lega Pro Prima Divisione in Italy with Portogruaro-Summaga, Madaschi was previously a team mate of Carl Valeri at Grosseto in 2005 following stints at Partick Thistle & Dundee United in Scotland. Madaschi was also member of the Qantas Olyroos team that represented Australia at the 2004 Athens Olympic Games.
The Qantas Socceroos will assemble for a training camp in Dubai ahead of their 2010 FIFA World Cup™ Asian Qualifier Round 4 match against Qatar in Doha on Saturday 6 June, before returning to Australia to face Bahrain in Sydney on Wednesday 10 June and then Japan in Melbourne on Wednesday 17 June.
The Qantas Socceroos need only a point from the three remaining qualifier matches to secure a place at the 2010 FIFA World Cup™ in South Africa.
Australian fans can show their support the Qantas Socceroos in their journey to South Africa by purchasing tickets from Ticketek either online (www.ticketek.com.au), over the phone (132 849) or at any Ticketek outlet or agency.
All Qantas Socceroos matches will be broadcast "Live and Exclusive" on FOX SPORTS.
QANTAS SOCCEROOS SQUAD - Wednesday 27 May 2009
Mark BRESCIANO - U.S. Citta di Palermo ITALY 48 (11) Jacob BURNS - FC Unirea Valahorum ROMANIA 9 (0) Tim CAHILL - Everton	ENGLAND	31 (14) Nick CARLE - Crystal Palace FC	ENGLAND	7 (0) David CARNEY - Sheffield United FC ENGLAND 18 (1) Scott CHIPPERFIELD - FC Basel	SWITZERLAND 60 (12) Chris COYNE - Colchester United FC ENGLAND 5 (0) Jason CULINA - Gold Coast United AUSTRALIA 38 (1) Bruce DJITE - Genclerbirligi SK	TURKEY 7 (0) Richard GARCIA - Hull City FC	ENGLAND	4 (0) Vincenzo GRELLA - Blackburn Rovers ENGLAND 37 (0) Brett HOLMAN - AZ Alkmaar HOLLAND 23 (1) Mile JEDINAK - Genclerbirligi SK TURKEY	4 (0) Brad JONES - Middlesbrough FC ENGLAND 1 (0) Josh KENNEDY - Karlsruher SC	GERMANY	12 (6) Harry KEWELL - Galatasaray SK	TURKEY 39 (13) Adrian MADASCHI - Portogruaro-Summaga	ITALY 4 (2) Scott McDONALD - Celtic FC SCOTLAND 11 (0) Mark MILLIGAN - Shanghai Shenhua CHINA 6 (0) Lucas NEILL - West Ham United FC ENGLAND 48 (0) Jade NORTH - Incheon United FC KOREA REPUBLIC 23 (0) Michael PETKOVIC - Sivasspor TURKEY 6 (0) Mark SCHWARZER - Fulham FC	ENGLAND	65 (0) Matthew SPIRANOVIC - FC Nurnberg GERMANY 2 (0) Shane STEFANUTTO -	FC Lyn Oslo NORWAY 1 (0) Mile STERJOVSKI - Derby County FC ENGLAND 39 (7) Carl VALERI - U.S. Grosseto FC ITALY 16 (0) Dario VIDOSIC - FC Nurnberg GERMANY - Luke WILKSHIRE - FK Dinamo Moscow RUSSIA 33 (0) Rhys WILLIAMS - Middlesbrough FC ENGLAND -
Iredale to make fresh start at German club VfL Wolfsburg
Teenage Australian forward John Iredale has landed with German outfit VfL Wolfsburg. The 19-year-old, who was included in Caltex Socceroos head coach Graham Arnold?s inaugural training camp in Turkey in September 2018, will join up with the Wolves' under-23 side for the 2019/
LIVE STREAM: The Caltex Socceroos' FIFA World Cup draw
The first step in the Caltex Socceroos journey to the FIFA World Cup 2022 in Qatar will be known tonight (Wednesday) with the official draw for the next phase of qualification in the Asian Football Confederation (AFC). As one of the top-ranked nations in the AFC, Australia are
Qualifying for the 2022 FIFA World Cup: Everything you need to know
There is nothing like playing at the FIFA World Cup but to earn the right to be among the best 32 nations on the planet, first you need to qualify. And that process is set to get underway for the Caltex Socceroos in September when the next phase of qualifying for the AFC begin
Australia to discover opponents as Qatar quest commences
The Caltex Socceroos will discover which nations they will play in their first phase of FIFA World Cup Qatar 2022 qualifying tonight when Asia?s Preliminary Joint Qualification Round 2 Draw is conducted at AFC House in Kuala Lumpur, Malaysia. From 7.00pm (AEST) on Wednesday,
Taggart makes K-League All Stars to face Ronaldo's Juventus
Adam Taggart?s red-hot K-League form has earned him a shot at Cristiano Ronaldo and Juventus. The Caltex Socceroos striker has been voted in the K-League All Stars squad for the clash against the Italian champions on July 26. And it?s hard to argue with his selection given
Andrew Redmayne recollects the Hyundai A-League 2019 Grand Final shootout
Caltex Socceroos debutants receive signed jerseys
Amini and Son exchange jerseys
Full-time highlights: Korea Republic v Australia
Andrew Redmayne denies Son Heung-min
Official Partners of the Caltex Socceroos
Locked Bag A4071
Sydney South,
My Football Live app


Nothing kills a festive holiday party buzz faster than a wineglass smashing on your living room floor. Sure, if a guest drops an acrylic glass you'll still have a mess to sop up—but you won't have to worry about tiny shards of glass causing a bloodbath as the party progresses. And with acrylic glasses as stylish as these from Jung Lee, you won't even miss the real thing: Acrylic Green Milly Tumbler, $25. Acrylic Victoria & Albert Grey Goblet, $22. Acrylic Victoria & Albert Green Footed Coupe, $22. Yes, I know they're spendy. But since they're virtually indestructible, you won't have to replace them every few months. Can't say that about a crystal flutes. Plus, they're durable enough to pack for a day at that beach or a picnic in the park, so just think of all the cash you'll save on red Solo cups. Would you break out these smash-proof glasses for your holiday party? Or do you insist on the real thing?
Acrylic Green Milly Tumbler, $25. Acrylic Victoria & Albert Grey Goblet, $22. Acrylic Victoria & Albert Green Footed Coupe, $22.
Yes, I know they're spendy. But since they're virtually indestructible, you won't have to replace them every few months. Can't say that about a crystal flutes. Plus, they're durable enough to pack for a day at that beach or a picnic in the park, so just think of all the cash you'll save on red Solo cups.
Would you break out these smash-proof glasses for your holiday party? Or do you insist on the real thing?


text:
import java.util.List;

import redis.clients.jedis.Jedis;
public class RedisListJava {
   public static void main(String[] args) {
      //Connecting to Redis server on localhost

      Jedis jedis = new Jedis("localhost", 6379);
      jedis.auth("foobared");
      jedis.select(2);
      jedis.set("foo", "bar");
      System.out.println("Connection to server sucessfully");
      //store data in redis list
      jedis.lpush("tutorial-list", "Redis");
      jedis.lpush("tutorial-list", "Mongodb");
      jedis.lpush("tutorial-list", "Mysql");
     // Get the stored data and print it
     List<String> list = jedis.lrange("tutorial-list", 0 ,5);
     for(int i=0; i<list.size(); i++) {
     System.out.println("Stored string in redis:: "+list.get(i));
     }
 }
}

redpajama_set_name: RedPajamaGithub


text:
Category Archives: STAAR
Hardeman Elementary earns all possible distinctions in 2016 accountability ratings
The Texas Education Agency recently announced that "more than 400 campuses that achieved a Met Standard rating in the 2016 state accountability ratings also earned all distinction designations applicable to their individual school." Hardeman Elementary was one that earned the maximum number of distinctions.
Elementary campuses may receive distinctions in six areas: academic achievement in reading/ELA, academic achievement in math, academic achievement in science, top 25 percent in student progress, top 25 percent in closing performance gaps, and postsecondary readiness. Secondary campuses may also receive distinctions for academic achievement in social studies. Distinctions are based on comparisons between individual schools and a 40-campus group with similar student demographics. BISD had 26 of the 31 campuses received at least one distinction. Hardeman Elementary received the maximum possible, with Watauga and Smithfield middle schools, and Green Valley and Smithfield elementary schools receiving six of seven and five of six respectively. A total of 85 distinctions were awarded to campuses across the District, 21 more than last year.
According to the Sept. 14, 2016 TEA press release, " 'Earning one or more campus distinctions is noteworthy and should be a source of pride in a community,' said Commissioner of Education Mike Morath. 'Earning all possible distinctions is a significant accomplishment and should signal to parents that there is extraordinary work taking place on that campus.'
"Last month, TEA released the 2016 state accountability ratings for more than 1,200 school districts and charters, as well as more than 8,600 campuses statewide. The ratings revealed that approximately 94 percent of school districts and charters across Texas have achieved the rating of Met Standard.
"To view the 2016 state accountability ratings and distinction designations for all districts, charters and campuses, visit the Texas Education Agency website athttp://tea.texas.gov/2016Accountability.aspx."
Comments (0) | | Categories: #BISDShines, STAAR, TEA
Birdville ISD Earns Highest Rating Under New State Accountability Standards
The Texas Education Agency (TEA) announced the 2016 district and school accountability ratings under the State of Texas Assessment of Academic Readiness (STAAR) tests. Birdville ISD and 31 district campuses earned a rating of Met Standard, while Shannon High School earned a rating of Met Alternative Standard. These are the highest ratings available in the state's accountability system.
"I am proud Birdville ISD and every campus once again earned a Met Standard rating under the state's more rigorous accountability system," Superintendent Darrell Brown said. "This is a reflection of the continued commitment to teaching and learning by our students and staff."
To receive a Met Standard rating, the District and campuses had to meet target scores in Index 3 and Index 4, and either Index 1 or Index 2. The District and all campuses met targets in all four indexes.
Index 1 – Student Achievement, evaluates performance on STAAR across all subjects and all student groups at the satisfactory performance standard.
Index 2 – Student Progress, evaluates the academic growth of students in reading and math for 10 student groups, including all students, seven race/ethnicity groups, English language learners and students served by special education.
Index 3 – Closing Performance Gaps, evaluates two levels of performance of students who are economically disadvantaged and, as applicable, students from the two lowest performing race/ethnicity groups from the prior year.
Index 4 – Postsecondary Readiness, evaluates student performance in all tested grade levels against Level II final standards. High schools and districts are also evaluated on graduation rates, the percentage of students graduating on Recommended and Distinguished/Advanced plans, and on a postsecondary college and career readiness indicator based on meeting the Texas Success Initiative (TSI) criteria, completion of advanced/dual credit courses, or enrollment in a coherent sequence of career and technology education courses.
Academic highlights from 2016 include:
BISD test scores exceeded the state average on STAAR in all subject areas for grades three through eight.
Third-grade students exceeded the state average on the STAAR reading test by seven percentage points.
Fourth-grade students exceeded the state average on the STAAR reading test by seven percentage points.
Fifth-grade students exceeded the state average on the STAAR science test by seven percentage points.
Sixth-grade students exceeded the state average on the STAAR math test by seven percentage points.
Seventh-grade students exceeded the state average on the STAAR math test by 10 percentage points.
Eighth-grade students exceeded the state average on the STAAR science test by six percentage points.
BISD students scored one percentage point above the state average on the Algebra 1 EOC exam.
BISD students scored two percentage points above the state average on the Biology EOC exam.
BISD students scored two percentage points above the state average on the English I EOC exam.
BISD students scored five percentage points above the state average on the English II EOC exam.
BISD students scored two percentage points above the state average on the U.S. History EOC exam.
Comments (0) | | Categories: #BISDShines, STAAR

redpajama_set_name: RedPajamaCommonCrawl


text:
Yellow nail syndrome: a review
Stéphane Vignes1 &
Robert Baran2
Orphanet Journal of Rare Diseases volume 12, Article number: 42 (2017) Cite this article
Yellow nail syndrome (YNS; OMIM 153300, ORPHA662) is a very rare disorder that almost always occurs after 50 years of age but a juvenile or familial form has also been observed. YNS is diagnosed based on a triad associating yellow nail discoloration, pulmonary manifestations (chronic cough, bronchiectasia, pleural effusion) and lower limb lymphedema. Chronic sinusitis is frequently associated with the triad. YNS etiology remains unknown but a role of lymphatic impairment is usually evoked. YNS is more frequently isolated but may be associated in rare cases with autoimmune diseases, other clinical manifestations implicating lymphatic functions or cancer and, hence, is also considered a paraneoplastic syndrome. YNS management is symptomatic and not codified. YNS can resolve spontaneously. Oral vitamin E alone or even better when associated with triazole antifungals may achieve partial or total disappearance of nail discoloration. Pleural effusion can be treated surgically, with decortication/pleurectomy or pleurodesis. Antibiotic prophylaxis is prescribed for bronchiectasia with chronic sputum production. Lymphedema treatment is based on low-stretch bandages and the wearing of elastic compression garments combined with skin care, exercises and, as needed, manual lymph drainage.
The first case of yellow nail syndrome (YNS; OMIM 153300, ORPHA662) was probably reported by Heller in 1927 [1], but Samman & White described the first series of patients who had yellow nails associated with lymphedema in 1964 [2]. That report included 13 patients (six men, seven women; age range at onset 25–65 years), all of whom had very slow measured nail growth associated with abnormal nail-plate discoloration, ranging from pale yellow to dark greenish, and frequent onycholysis. Eight of them had ankle edema; one patient each had facial edema or Milroy's disease (familial form of primary lymphedema). Four patients' limb lymphangiograms showed lymphatic abnormalities, such as tortuous, dilated or hypoplastic vessels, which the authors considered suggestive of lymphatic dysfunction or defective lymph drainage being responsible for YNS. In this review, we analyze the available literature on this subject, describing clinical characteristics, explorations, associated diseases and management of this rare syndrome.
The literature search of the PubMed database used the words "yellow nail syndrome" for articles written in English or French. Other references cited in the identified articles were also considered.
YNS is characterized by a triad of thickened yellow nails, primary lymphedema and respiratory manifestations. It is an acquired condition of unknown etiology. It is a syndrome – not a disease – that is associated with conditions as different as diseases implicating the lymphatic system, autoimmune diseases or cancers. Whereas Samman & White's first description of YNS included only nail discoloration, Emerson added pleural effusion to the diagnostic criteria [3]. Among the three clinical YNS characteristics (yellow nail syndrome, respiratory tract involvement, lymphedema), only two are required to diagnose YNS but it is difficult to call the entity YNS without nail abnormality [4]. Moreover, the three components are not necessarily present simultaneously, and may appear individually and sequentially, thereby making YNS diagnosis difficult. The complete triad is present only in 27–60% of the patients [5–10] (Table 1). The percentage differences of a given clinical manifestation may be attributed to the medical specialty that recruited the patients.
Table 1 YNS clinical manifestations found in six large series of patients
No precise data are available to determine the exact prevalence of YNS, as fewer than 400 cases have been published in the literature, with an estimated prevalence <1/1,000,000. Cases have been described in all countries worldwide. YNS most often occurs in adults over 50 years old, with no sex predominance [5–7]. Pediatric forms are very rarely reported [11–21]: YNS may be present at birth (congenital) or develop before the age of 10 years [8].
A familial form of YNS has very rarely been described [5, 22–24], affecting two siblings [25, 26] or a family with eight cases in four sibships over two generations [22]. The very few reported familial cases mimic a dominant inheritance pattern, which is not supported by any genetic evidence [5]. YNS may be associated with intellectual disability, in which case it evokes a more complex syndrome [25] or occurs in cases of consanguinity [17].
Diagnosis and diagnostic methods
Yellow nails
Yellow nails are the main clinical manifestation leading to YNS diagnosis. However, the possible interval between the first clinical sign (lymphedema, lung manifestations) and nail discoloration hinders affirmation of the YNS diagnosis. That yellowing represents a subset of chromonychia, defined as pathological nail discoloration, especially xanthonychia (yellow nail coloration). Nail discoloration varies from pale yellow to more or less dark greenish [27]. The nail plate becomes thickened, with an enhanced transverse curvature (overcurvature), sometimes with a notable hump, cross-ridging, very hard (scleronychia) and difficult-to-trim nail, and cuticle disappearance [28]. Usually opaque, the lunula disappears because of nail hyperkeratosis [27] (Fig. 1). Erythema may be seen in the proximal nail fold, frequently associated with chronic paronychia). Onycholysis (distal nail plate–nail bed separation) may occur with possible proximal spreading, leading to complete nail shedding [29, 30]. Longitudinal growth of the affected nail (0.23 mm per week) was half that of a normal nail (0.46 mm per week) [2, 31]. The affected nail's thickness (0.97 mm) was double that of a normal nail (0.57 mm), suggesting that the nail that grows half as fast and twice as thick [31].
Yellowing of all 10 (a) finger and (b) toe nails
Pulmonary manifestations
Lung involvement in YNS, which occurred in 56–71% of the patients, diversely affected some parts of the respiratory tract with a variety of clinical manifestations [6–8]. Chronic cough is the most frequent pulmonary manifestation seen in 56% of YNS patients [6], with pleural effusions found in 14–46% of the patients [6, 7].
Based on their retrospective systematic review of more than 150 patients described in publications identified with the search terms "pleural effusion" and "YNS", Valdés et al. recently reported the characteristics of these pleural effusions [32]: 68.3% were bilateral; the fluid appeared serous in 75%, milky (chylothorax) in 22% and purulent (empyemas) in 3.5%; 95% of effusions were described as exudates (median protein level: 4.2 g/dl) and 5% as transudates that harbored a median nucleated cell count of 1540 cells/mm3 with 96% lymphocytic predominance.
However, sputum bacteria (Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis) are the same in idiopathic and YNS-associated bronchiectasias [33]. Recurrent pneumonias occur in 22% of the patients. Also, bilateral apical fibrosis, patchy alveolar infiltrates and cystic lesions are very rarely observed in YNS patients [33, 34].
YNS patients' pulmonary function test results are usually normal or may indicate a moderate-to-severe restrictive syndrome attributable to pleural effusions [4]. Extremely rare patients may have mixed obstructive–restrictive syndrome or decreased diffusion capacity [6]. Histological examination of pleural biopsies revealed normal morphology or that of chronic fibrosing pleuritis, and did not provide any further information; biopsies are usually not contributive [32]. Bronchiectasias are present in 44%. Chest computed-tomography (CT) scan is the best imaging technique to diagnose bronchiectasia, which, in YNS patients, is significantly less extensive, severe and with lower bronchial wall thickness scores than in matched idiopathic bronchiectasia patients [33].
Lymphedema is a clinical feature of YNS, occurring in 29–80% of the reported series, and may be the first sign of the disease in about one-third of them [6–8]. Lymphedema characteristics do not differ from those of primary lymphedema. It involves the lower limbs, especially bilateral and below the knee (Fig. 2). The increased volume of the lymphedematous limb is caused by excess lymph accumulation but also fibrosis resulting from fibroblast stimulation and excess adipose tissue due to adipocyte stimulation [35, 36]. Stemmer's sign (inability to pinch the skin on the dorsal side or the base of the second toe) is pathognomonic of lymphedema and is fibrosis-related. Superficial edema is responsible for the more-or-less present pitting edema. Lymphedema is a chronic disease, with a major tissular component leading to incomplete reversibility under treatment. Although cellulitis (erysipelas) is the main lymphedema complication, discomfort, esthetic prejudice and diminished quality of life also complicate the disease [37, 38].
Bilateral lower limb lymphedema involving the feet, ankles and calves, with accentuation of the flexion folds
Acute or chronic rhinosinusitis is very common in YNS patients, estimated between 14 and 83% [5–10]. The maxillary sinus is the most frequently affected, followed by ethmoid, frontal and sphenoid [9] (Fig. 3). Nasal symptom onset may precede nail changes by a few years, appear simultaneously or arise subsequently. Clinical signs include daily mucopurulent rhinorrhea, nasal obstruction and frequent post-nasal drip. Nasal airway examination usually finds narrowed nasal pathways, mucosal inflammation with variable enlargement of the turbinates and the presence of mucopus. Other symptoms may be associated, e.g., headaches or recurrent facial pain. Non-contrast sinus CT scans show mucosal thickening, with fluid levels sometimes reported.
Sinus computed-tomography scan: note the subtotal opacity of the left maxillary sinus and ethmoidal sinusitis
Other manifestations
Very rare ocular involvement has been reported: chemosis, corneal micropannus (vascularized sheet of fibrous tissue overlying the cornea), eyelid lymphedema, thickened conjunctiva [39, 40]. Anecdotal associations have also been described: anhydrosis, pectus excavatum, eosinophilia–myalgia syndrome, bullous stomatitis, sarcoidosis and Raynaud's phenomenon, cerebral aneurysm and pancytopenia [6].
Among children with YNS, 75% had lung manifestations (infections, pleural effusions, bronchial dilations and/or bronchial cysts) and ear-nose-throat symptoms in 31%, with a moderate female predominance [20]. Lymphedema prevalence ranged from 56 to 80% of YNS children and may appear later than the nail discoloration [8].
Although YNS etiology of remains unknown, some hypotheses were advanced. Lymphatic involvement is often evoked to explain lymphedema, pleural effusion (particularly chylothorax) or nail discoloration but it is difficult to implicate it in bronchiectasia and sinusitis. Lymphatic impairment is not easy to confirm. Four YNS patients underwent lower limb direct lymphangiography, less used at present, but lymphatic abnormalities were noted only in the patient with severe lymphedema. Quantitative limb lymphoscintigraphy with 99mTc-colloidal antimony sulfide revealed less activity (percentage uptake) in the draining lymph nodes (inguinofemoral or axillary) [41]. Moreover, the uptake percentages in the axillary/inguinal lymph nodes of the YNS group were significantly lower than those of the normal controls but significantly higher than those of subjects with primary or secondary lymphedema, hence more suggestive of impaired lymph transport than the lymphatic hypoplasia/aplasia seen in true primary lymphedema. Furthermore, the YNS group without lower limb edema had better lymphatic drainage than those with edema [42] (Fig. 4). Maldonado et al. thought that YNS pathophysiology might be attributable to microvasculopathy associated with protein leakage rather than functional lymphatic impairment [43]. Notably, nailfold capillaroscopy occasionally showed dilated and tortuous capillary loops [44].
Lower-limb lymphoscintigraphy images were obtained 40 min after injecting 99mtechnetium-labeled colloidal albumin into two patients with the complete YNS triad: moderate lymphostasis and slightly decreased (a) or absent (b) inguinal lymph-node uptake
Defective lymphatic drainage might be responsible for the slow growth and thickened nails observed in YNS, and may reflect subungual tissue sclerosis leading to lymphatic obstruction. Light microscopy examination of sections of nail-matrix tissue revealed replacement of the normally loose fibrovascular subungual stroma by dense, fibrous tissue (composed of dense collagen deposits) extending from the immediate subepithelial stroma to a depth of 2.5 mm. Numerous ectatic, endothelium-lined channels were prominent within the fibrotic stroma [45]. Fibrosis and dilated lymphatic vessels were also seen in the parietal pleura of a YNS patient [46, 47]. The accumulation of lipofuscin pigment was advanced to explain the yellow discoloration [48], whereas abnormal nail keratinization might be explained by the presence electron microscopy-visualized keratohyalin granules, not found in normal adult nails.
More recently, it was hypothesized that titanium, especially titanium dioxide, might play a role in YNS. High titanium levels (determined by energy dispersive X-ray fluorescence) were detected in the nails of YNS patients but not in control nails. The authors postulated that titanium ions were released from titanium implants (inlays, crown) in the teeth or jaws through the galvanic action of amalgam or localized oxidative action of fluorides [49–51]. Other sources of titanium ions were also suggested: joint implants, surgical staples, foods (chewing gum to try to explain YNS in children), medication excipients, cosmetics (sunscreen, moisturizers, shampoo, toothpaste) [50, 52]. Titanium's hypothetical role remains possible, but probably not sufficient, because its presence in other organs (liver, spleen, lymph nodes, lung) of autopsied patients was not accompanied with nail yellowing [53].
Associated diseases
Several infants had YNS associated with non-immune hydrops fetalis; this association is probably not fortuitous [54]. Non-immune hydrops fetalis was present at birth [20, 55]. A child with YNS had a brother who died of non-immune hydrops fetalis, suggesting a possible relationship between the two diseases [17].
YNS is very rarely associated with primary intestinal lymphangiectasia (Waldmann's disease) (OMIM 152800, ORPHA90362) or lymphedema–distichiasis syndrome (OMIM 153400, ORPHA33001), suggesting that these entities have overlapping characteristics, including lymphatic impairment [56, 57]. Waldmann's disease is characterized by primary intestinal lymphangiectasia, with lymph leakage into the bowel lumen leading to hypoalbuminemia, hypogammaglobulinemia and lymphopenia [58]. Distichiasis is defined as double or more rows of eyelashes localized on the Meibomian gland orifices [59].
The YNS association with malignant disease raises the hypothesis that it might be a paraneoplastic syndrome but that notion remains controversial. The frequency of cancer being diagnosed concurrently or closely thereafter in YNS patients was estimated at 4/41 [6] and 1/21 [7]. Various types of cancers were associated with YNS: bronchial carcinoma [60, 61], breast [7, 62, 63], non-Hodgkin lymphoma [64, 65], gallbladder [6, 66], larynx [67], renal cell carcinoma [6], endometrium [68], melanoma [3], multiple myeloma after hematopoietic stem-cell transplantation [69] or precancerous mycosis fungoides [28]. The YNS-to-cancer-diagnosis interval ranges from days to years, with gradual development of the complete YNS triad [61].
YNS was occasionally associated with autoimmune diseases [70], immunodeficiency disorders, such as common variable immunodeficiency, combined T- and B-cell deficiency [70, 71], Guillain–Barré syndrome [72], nephrotic syndrome [73, 74], Hashimoto's thyroiditis, severe hypothyroidism or hyperthyroidism [75–77], xanthogranulomatous pyelonephritis [78] and rheumatoid arthritis even without thiol-analog use [79].
Immunological studies on YNS patients are very scarce. Isolated case reports associated YNS with IgA deficiency [22] or hypogammaglobulinemia [80]. Bokszczanin & Levinson described a 57-year-old woman with YNS and poor selective responses after vaccination against Streptococcus pneumoniae and Haemophilus influenzae [81], which might explain, in part, the recurrent lung or sinus infections in YNS. Gupta et al. reported lymphopenia in two YNS patients (one with common variable immunodeficiency) with low percentages of CD4+ T cells, high percentages of CD8+ T cells and severe naïve CD4+ and CD8+ T-cell deficits responsible for muted T-cell responses to antigens. A suggested mechanism for diminished naïve T-cell subsets might be less thymus output (thymus involution and/or apoptosis) [70]. It is of interest to note that, in another rare disease with lymphatic abnormality, primary intestinal lymphangiectasia (Waldmann's disease), immunological investigation results were similar to those of YNS patients [82].
Differential diagnosis of nail discoloration
d-Penicillamine, bucillamine and tiopronin are three thiol compounds used for long-term treatment of rheumatoid arthritis. For the rare cases of drug-related YNS, nail discoloration was the first manifestation in 88% of them, but it was less frequently associated with pleural effusion and lymphedema than in YNS not drug-related [83, 84]. Competitive inhibition of disulfide-binding in keratin biosynthesis is postulated to explain the major slowing of nail plate growth in bucillamine-treated patients. Moreover, thiol drugs contain cysteine, which is also a major nail component. After bucillamine withdrawal, nail discoloration declined in over 90% of the affected patients but lymphedema and pulmonary manifestations were attenuated in only 30–35% [84]. Gold and methotrexate, also used to treat rheumatoid arthritis, are less suspected of being associated with YNS [85].
Nail yellowing is abnormal and may be attributable to something other than YNS. Nail infection or mycosis should be ruled out before considering YNS. Candida-, Aspergillus- or dermatophyte-caused nail mycosis may cause such discoloration. Pseudomonas aeruginosa, via production of the blue–green pigments pyoverdin and pyocyanin, may be responsible for chloronychia (green rather than yellow nail discoloration) in the elderly [86]. Chloronychia is more common in homemakers, barbers, dishwashers, bakers and medical personnel.
In children and adults, differential diagnoses include planus lichen, psoriasis or alopecia areata, chronic paronychia, onychogryphosis and acquired pachyonychia [87–89]. Yellow nail discoloration may also have rare local and toxic causes (Table 2) [90].
Table 2 Rare, usually work-related, local toxic causes of yellow nail discoloration, from [90]
YNS treatment is not codified. YNS may resolve in few months without treatment [91] or, when it is a paraneoplastic syndrome, after cancer therapy [62].
Yellow nail changes
The main aim is to improve the frequently unesthetic nail appearance and associated pain, due, in part, to onycholysis. A few drugs have been proposed to treat the nail discoloration with inconsistent efficacy. None of the following treatments can be recommended systematically to treat YNS.
Systemic treatments of yellow nails
Oral vitamin E is the only agent that successfully treated YNS [48, 92–95]. Oral α-tocopherol (vitamin E) was frequently prescribed at 1000–1200 IU/day, with incomplete or inconstant efficacy. Norton's hypothesized, as follows, that vitamin E would be effective: lipofuscin pigments, possibly responsible for nail yellowing, are derived from colorless lipid precursors, transformed by oxidation in tissue to produce varying degrees of yellow; vitamin E has proven in vitro antioxidant properties, and in vivo might protect cell membranes against free-radical–mediated oxidative damage, thereby potentially blocking lipofuscin-pigment production [48].
Although YNS is not caused by fungal infection, triazole antifungals were regularly used to treat it. Itraconazole, given at 400 mg/day for 1 week/month for 6 months, achieved only two mild attenuations and two cures among eight patients (one relapsed after drug discontinuation) [96]. Among the 13 patients who took oral fluconazole (300 mg once weekly) and oral α-tocopherol (1000 IU/day), two benefited from clinical improvement and 11 were considered clinical cures [97], without any efficacy on other YNS manifestations. One of the hypotheses to explain that partial efficacy is based on azole antifungal stimulation of linear nail growth [98, 99].
Oral zinc sulfate supplementation (300 mg daily) obtained attenuation of nail yellowing or growth and lymphedema after 8 months of treatment but no modification of pulmonary manifestations [95].
Clarithromycin (400 mg/day, 6 years) successfully treated one patient [100].
A patient with common variable immunodeficiency treated with subcutaneous immunoglobulin mounted good responses in terms of frequency of infections, lymphedema and pleural effusions [70].
Local treatments
Intralesional steroids, such as topical triamcinolone acetonide (5 mg/ml/injection, 0.1–0.2 ml for each affected nail), were proposed alone or combined with fluconazole and vitamin E [92, 101].
In a first study published in 1991, Williams et al. prescribed topical vitamin E; the treated nails improved clinically and growth rates rose [94]. In a randomized study using a vitamin E preparation (solution of 20,000 IU of tocopherol acetate/fluid ounce of safflower oil) applied twice daily to the nails), no difference (appearance or nail growth) versus placebo was observed after 6 months of administration [23].
Symptomatic treatments are prescribed. Patients may receive antibiotics for acute exacerbation of bronchiectasia, whereas, for patients with poor symptom control and/or recurrent exacerbations, low-dose antibiotic prophylaxis, such as oral azithromycin (usually 250 mg 3 times/week), achieved attenuation of chest symptoms for the majority of them [33]. Physiotherapy training (postural drainage, chest physiotherapy, flutter valve), combined or not with antibiotic prophylaxis, is also prescribed to help patients self-manage their chronic expectoration.
Vaccinations against flu and pneumococci are strongly recommended. Surgical intervention of recurrent and/or large pleural effusions is useful: decortication/pleurectomy, pleurodesis (talc [47, 102], picibanil [103], quinacrine [4]) and pleural–peritoneal shunts were the most effective treatments of symptomatic pleural effusions with, respectively, 89, 82 and 67% partial or complete responses [33].
Octreotide, a somatostatin analog, was also used to treat YNS pleural effusions or chylous ascites and lymphedema, and generated positive responses [47, 104–107]. Somatostatin analogues reduce intestinal lipid absorption and lower the triglyceride concentration in the thoracic duct in animals [108]. Those actions could explain the diminution of the chylous but not non-chylous effusions present in most YNS patients. Octreotide was initially administered subcutaneously (0.5 mg twice daily) to ensure safety, followed by the long-acting repeatable formulation (30 mg given once/month) with or without progressive dose diminution [105, 107]. One initial octreotide responder became "resistant", suggesting tachyphylaxis to long-lasting treatment, as previously described for acromegaly patients receiving chronic treatment. Lanreotide, an alternative somatostatin analog, may be useful for such cases [47, 109].
Complete decongestive therapy, also called complex or multimodal decongestive physiotherapy, is the term proposed by Michael Földi in the 1980s to define lymphedema treatment. This approach is divided into two separate phases [110]. The first, intended to obtain the most important lymphedema-volume reduction, is comprised of several components: low-stretch bandage, manual lymph drainage, skin/nail care (to detect and eliminate potential sites of entry for infection) and exercises, each having its own specific objective and role in limiting the impact of this disorder. The intensive strategy of this stage aims to achieve 30–40% lymphedema-volume reduction [111], eliminating only the fluid component of lymphedema. The second phase of complete decongestive therapy helps stabilize lymphedema volume over the long-term and is based on wearing a high-pressure elastic garment, exercises, skin care and, sometimes, manual lymph drainage [112]. Each patient should be offered several training sessions in validated specific patient-education programs to master the wrapping procedure and verify good understanding and implementation. Overnight bandaging at least three times per week is recommended during long-term maintenance. The aim of learning self-bandaging is to improve the patient's autonomy to manage his/her own lymphedema [113].
Treatment of acute sinusitis is based on antibiotics (amoxicillin–clavulanate (1.5–3 g/day), or, in the case of penicillin allergy, doxycycline (200 mg/day), fluoroquinolone (levofloxacin, 500 mg/day) or moxifloxacin (400 mg/day)) for 5–7 days [114]. Treatment of chronic sinusitis is not specific for YNS patients but global responses to medications, including short-course oral antibiotics, topical intranasal steroids, saline irrigation and topical or oral decongestant, are poor [115]. Surgical procedures may be necessary and are essentially based on endoscopic sinus surgery (endoscopic middle meatal antrostomy, conventional inferior meatal antrostomy) [116].
Spontaneous remission of the nail changes has been observed in up to 30% of the YNS patients, regardless of treatment [5]. Remission of nail changes was more likely for fingernails than toenails, perhaps because of persistent lower limb lymphedema, which might maintain the presumed lymphatic pathophysiology [5]. More generally, the attenuated discoloration is not associated with simultaneous regression of other systemic manifestations. In YNS associated with malignant disease, treatment of the latter may lead to attenuation or disappearance of the clinical YNS signs [62, 69]. In Maldonado et al.'s study, 17 of the 37 patients with available follow-up information died after a median of 82 months [6]. In that study, a Kaplan–Meier survival curve estimated median survival at 132 months, shorter than that of a paired-control population.
YNS is very rare disorder associating yellow nail discoloration, lung manifestations/sinusitis and lymphedema. It is more frequently isolated but may be associated with other diseases implicating the lymphatic system, autoimmune diseases or cancers. Its etiology remains unknown, although lymphatic impairment is regularly evoked in the literature. Titanium is a more recent hypothetical agent but so far remains unconfirmed to explain the syndrome. YNS treatment is symptomatic for each component: yellow nails, pulmonary manifestations/sinusitis, lymphedema. Vitamin E combined with fluconazole, usually prescribed to treat yellow nails, achieves partial or complete responses. Spontaneous resolution is also possible. Research is required to better understand and treat this rare and very poorly recognized disease.
YNS:
Yellow nail syndrome
Heller J. Die Krankheiten der Nagel. In: Jadassohn's Handbuch der Haut und Geschlechtskrankheiten, vol. 13 part 2. Berlin: Julius Springer; 1927. p. 423.
Samman PD, White WF. The yellow nail syndrome. Br J Dermatol. 1964;76:153–7. doi:10.1111/j.1365-2133.1964.tb14499.x.
Emerson PA. Yellow nails, lymphoedema, and pleural effusions. Thorax. 1966;21:247–53.
Hiller E, Rosenow 3rd EC, Olsen AM. Pulmonary manifestations of the yellow nail syndrome. Chest. 1972;61:452–8. doi:10.1378/chest.61.5.452.
Hoque SR, Mansour S, Mortimer PS. Yellow nail syndrome: not a genetic disorder? Eleven new cases and a review of the literature. Br J Dermatol. 2007;156:1230–4. doi:10.1111/j.1365-2133.2007.07894.x.
Maldonado F, Tazelaar HD, Wang CW, Ryu JH. Yellow nail syndrome: analysis of 41 consecutive patients. Chest. 2008;134:375–81. doi:10.1378/chest.08-0137.
Piraccini BM, Urciuoli B, Starace M, Tosti A, Balestri R. Yellow nail syndrome: clinical experience in a series of 21 patients. J Dtsch Dermatol Ges. 2014;12:131–7. doi:10.1111/ddg.12216.
Nordkild P, Kromann-Andersen H, Struve-Christensen E. Yellow nail syndrome – the triad of yellow nails, lymphoedema, and pleural effusions. A review of the literature and a case report. Acta Med Scand. 1986;219:221–7.
Varney VA, Cumberworth V, Sudderick R, Durham SR, Mackay IS. Rhinitis, sinusitis and the yellow nail syndrome: a review of symptoms and response to treatment in 17 patients. Clin Otolaryngol Allied Sci. 1994;19:237–40. doi:10.1111/j.1365-2273.1994.tb01222.x.
Pavlidakey GP, Hashimoto K, Blum D. Yellow nail syndrome. J Am Acad Dermatol. 1984;11:509–12. doi:10.1016/S0190-9622(84)70201-5.
Magid M, Esterly NB, Prendiville J, Fujisaki C. The yellow nail syndrome in an 8-year-old girl. Pediatr Dermatol. 1987;4:90–3. doi:10.1111/j.1525-1470.1987.tb00758.x.
Paradisis M, Van Asperen P. Yellow nail syndrome in infancy. J Paediatr Child Health. 1997;33:454–7. doi:10.1111/j.1440-1754.1997.tb01642.x.
Göçmen A, Küçükosmanoglu O, Kiper N, Karaduman A, Ozçelik U. Yellow nail syndrome in 10-year-old girl. Turk J Pediatr. 1997;39:105–9.
Yalçin E, Dogru D, Gönç EN, Cetinkaya A, Kiper N. Yellow nail syndrome in an infant presenting with lymphedema of the eyelids and pleural effusion. Clin Pediatr (Phila). 2004;43:569–72.
Douri T. Yellow nail syndrome in two siblings. Dermatol Online J. 2008;14:7.
Cebeci F, Celebi M, Onsun N. Non classical yellow nail syndrome in 6-year-old girl: a case report. Cases J. 2009;2:165. doi:10.1186/1757-1626-2-165.
Nanda A, Al-Essa FH, El-Shafei WM, Alsaleh QA. Congenital yellow nail syndrome: a case report and its relationship to nonimmune fetal hydrops. Pediatr Dermatol. 2010;27:533–4. doi:10.1111/j.1525-1470.2010.01259.x.
Siddiq I, Hughes DM. Yellow nails, lymphedema and chronic cough: yellow nail syndrome in an eight-year-old girl. Can Respir J. 2012;19:35–6.
Cecchini M, Doumit J, Kanigsberg N. Atypical presentation of congenital yellow nail syndrome in a 2-year-old female. J Cutan Med Surg. 2013;17:66–8.
Dessart P, Deries X, Guérin-Moreau M, Troussier F, Martin L. Syndrome des ongles jaunes: deux cas pédiatriques. Ann Dermatol Venereol. 2014;141:611–9. doi:10.1016/j.annder.2014.06.026.
Al Hawsawi K, Pope E. Yellow nail syndrome. Pediatr Dermatol. 2010;27:675–6. doi:10.1111/j.1525-1470.2010.01338.x.
Wells GC. Yellow nail syndrome with familial primary hypoplasia of lymphatics, manifest late in life. Proc Royal Soc Med. 1966;59:447.
Lambert EM, Dziura J, Kauls L, Mercurio M, Antaya RJ. Yellow nail syndrome in three siblings: a randomized double-blind trial of topical vitamin E. Pediatr Dermatol. 2006;23:390–5. doi:10.1111/j.1525-1470.2006.00251.
Razi E. Familial yellow nail syndrome. Dermatol Online J. 2006;12:15.
Kamatani M, Rai A, Hen H, Hayashi K, Aoki T, Umeyama K, et al. Yellow nail syndrome associated with mental retardation in two siblings. Br J Dermatol. 1978;99:329–33. doi:10.1111/j.1365-2133.1978.tb02005.x.
Kleinman PK. Congenital lymphedema and yellow nails. J Pediatr. 1973;83:454–6.
Baran R. Pigmentations of the nails (chromonychia). J Dermatol Surg Oncol. 1978;4:250–4.
Stosiek N, Peters KP, Hiller D, Riedl B, Hornstein OP. Yellow nail syndrome in a patient with mycosis fungoides. J Am Acad Dermatol. 1993;28:792–4. doi:10.1016/S0190-9622(09)80277-6.
Holzberg M. The nail in systemic disease. In: Baran R, de Berker DAR, Holzberg M, Thomas L, editors. Baran and Dawber's diseases of the nails and their management. 4th ed. Oxford: Wiley-Blackwell; 2012. p. 328–30.
Venencie PY, Dicken CH. Yellow nail syndrome: report of five cases. J Am Acad Dermatol. 1984;10:187–92. doi:10.1016/S0190-9622(84)70021-1.
Moffitt DL, de Berker DA. Yellow nail syndrome: the nail that grows half as fast grows twice as thick. Clin Exp Dermatol. 2000;25:21–3. doi:10.1046/j.1365-2230.2000.00563.x.
Valdés L, Huggins JT, Gude F, Ferreiro L, Alvarez-Dobaño JM, Golpe A, et al. Characteristics of patients with yellow nail syndrome and pleural effusion. Respirology. 2014;19:985–92. doi:10.1111/resp.12357.
Woodfield G, Nisbet M, Jacob J, Mok W, Loebinger MR, Hansell DM, et al. Bronchiectasis in yellow nail syndrome. Respirology. 2017;22:101–7. doi:10.1111/resp.12866.
Sacco O, Fregonese B, Marino CE, Mattioli G, Gambini C, Rossi GA. Yellow nail syndrome and bilateral cystic lung disease. Pediatr Pulmonol. 1998;26:29–33.
Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med. 1998;3:145–56.
Zampell JC, Aschen S, Weitman ES, Yan A, Elhadad S, De Brot M, et al. Regulation of adipogenesis by lymphatic fluid stasis: part I. Adipogenesis, fibrosis, and inflammation. Plast Reconstr Surg. 2012;129:825–34. doi:10.1097/PRS.0b013e3182450b2d.
Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): case–control study. BMJ. 1999;318:1591–4.
Okajima S, Hirota A, Kimura E, Inagaki M, Tamai N, et al. Health-related quality of life and associated factors in patients with primary lymphedema. Jpn J Nurs Sci. 2013;10:202–11. doi:10.1111/j.1742-7924.2012.00220.x.
Maisels DO, Korachi AO. Lymphoedema of the eyelids in the yellow nail syndrome. Br J Plast Surg. 1985;38:93–6.
Bourcier T, Baudrimont M, Borderie V, Mayaud C, Laroche L. Conjunctival changes associated with yellow nail syndrome. Br J Ophthalmol. 2002;86:930.
Marks R, Ellis JP. Yellow nails: a report of six cases. Arch Dermatol. 1970;102:619–23. doi:10.1001/archderm.1970.04000120037006.
Bull RH, Fenton DA, Mortimer PS. Lymphatic function in the yellow nail syndrome. Br J Dermatol. 1996;134:307–12. doi:10.1111/j.1365-2133.1996.tb07619.x.
Maldonado F, Ryu JH. Yellow nail syndrome. Curr Opin Pulm Med. 2009;15:371–5. doi:10.1097/MCP.0b013e32832ad45a.
D'Alessandro A, Muzi G, Monaco A, Filiberto S, Barboni A, Abbritti G. Yellow nail syndrome: does protein leakage play a role? Eur Respir J. 2001;17:149–52.
DeCoste SD, Imber MJ, Baden HP. Yellow nail syndrome. J Am Acad Dermatol. 1990;22:608–11. doi:10.1016/0190-9622(90)70081-R.
Solal-Céligny P, Cormier Y, Fournier M. The yellow nail syndrome. Light and electron microscopic aspects of the pleura. Arch Pathol Lab Med. 1983;107:183–5.
Brooks KG, Echevarria C, Cooper D, Bourke SC. Case-based discussion from North Tyneside General Hospital: somatostatin analogues in yellow nail syndrome associated with recurrent pleural effusions. Thorax. 2014;69:967–8. doi:10.1136/thoraxjnl-2014-205426.
Norton L. Further observations on the yellow nail syndrome with therapeutic effects of oral alpha-tocopherol. Cutis. 1985;36:457–62.
Berglund F, Carlmark B. Titanium, sinusitis, and the yellow nail syndrome. Biol Trace Elem Res. 2011;143:1–7. doi:10.1007/s12011-010-8828-5.
Decker A, Daly D, Scher RK. Role of titanium in the development of yellow nail syndrome. Skin Appendage Disord. 2015;1:28–30. doi:10.1159/000375171.
Ataya A, Kline KP, Cope J, Alnuaimat H. Titanium exposure and yellow nail syndrome. Respir Med Case Rep. 2015;16:146–7. doi:10.1016/j.rmcr.2015.10.002.
Hsu TY, Lin CC, Lee MD, Chang BP, Tsai JD. Titanium dioxide in toothpaste causing yellow nail syndrome. Pediatrics. 2017;139:e20160546. doi:10.1542/peds.2016-0546.
Dos Santos VM. Titanium pigment and yellow nail syndrome. Skin Appendage Disord. 2016;1:197. doi:10.1159/000445722.
Slee J, Nelson J, Dickinson J, Kendall P, Halbert A. Yellow nail syndrome presenting as non immune hydrops: second case report. Am J Med Genet. 2000;93:1–4.
Govaert P, Leroy JG, Pauwels R, Vanhaesebrouck P, De Praeter C, Van Kets H, et al. Perinatal manifestations of maternal yellow nail syndrome. Pediatrics. 1992;89:1016–8.
Desramé J, Béchade D, Patte JH, Jean R, Karsenti D, Coutant G, et al. Syndrome des ongles jaunes associé à des lymphangiectasies intestinales. Gastroenterol Clin Biol. 2000;24:837–40. doi: GCB-08-2000-24-8-0399-8320-101019-ART16.
Duhra PM, Quigley EM, Marsh MN. Chylous ascites, intestinal lymphangiectasia and the 'yellow-nail' syndrome. Gut. 1985;26:1266–9.
Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet J Rare Dis. 2008;3:5. doi:10.1186/1750-1172-3-5.
Brice G, Mansour S, Bell R, Collin JR, Child AH, Brady AF, et al. Analysis of the phenotypic abnormalities in lymphoedema–distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet. 2002;39:478–83. doi:10.1136/jmg.39.7.478.
Thomas PS, Sidhu B. Yellow nail syndrome and bronchial carcinoma. Chest. 1987;92:191. doi:10.1378/chest.92.1.191a.
Carnassale G, Margaritora S, Vita ML, Mariantonia A, Congedo MT, Cusumano G, et al. Lung cancer in association with yellow nail syndrome. J Clin Oncol. 2011;29:e156–8. doi:10.1200/JCO.2010.31.8402.
Iqbal M, Rossoff LJ, Marzouk KA, Steinberg HN. Yellow nail syndrome: resolution of yellow nails after successful treatment of breast cancer. Chest. 2000;117:1516–8. doi:10.1378/chest.117.5.1516.
Gupta AK, Davies GM, Haberman HF. Yellow nail syndrome. Cutis. 1986;37:371–4.
Ginarte M, Monteagudo B, Toribio J. Yellow nail syndrome and lung lymphoma. Clin Exp Dermatol. 2004;29:432–4. doi:10.1111/j.1365-2230.2004.01541.x.
Sève P, Thieblemont C, Dumontet C, Bouafia F, Arnaud P, Hequet O, et al. Skin lesions in malignancy. Case 3. Yellow nail syndrome in non-Hodgkin's lymphoma. J Clin Oncol. 2001;19:2100–1. doi:10.1200/JCO.2001.19.7.2100.
Burrows NP, Jones RR. Yellow nail syndrome in association with carcinoma of the gall bladder. Clin Exp Dermatol. 1991;16:471–3. doi:10.1111/j.1365-2230.1991.tb01240.x.
Guin JD, Elleman JH. Yellow nail syndrome. Possible association with malignancy. Arch Dermatol. 1979;115:734–5. doi:10.1001/archderm.1979.04010060042027.
Mambretti-Zumwalt J, Seidman JM, Higano N. Yellow nail syndrome: complete triad with pleural protein turnover studies. South Med J. 1980;73:995–7.
Grégoire C, Guiot J, Vertenoeil G, Willems E, Hafraoui K, Corhay JL, et al. Yellow nail syndrome after allogeneic hematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clin Belg. 2016;6:1–3. doi:10.1080/17843286.2015.1122872.
Gupta S, Samra D, Yel L, Agrawal S. T and B cell deficiency associated with yellow nail syndrome. Scand J Immunol. 2012;75:329–35. doi:10.1111/j.1365-3083.2011.02653.x.
Siegelman SS, Heckman BH, Hasson J. Lymphedema, pleural effusions and yellow nails: associated immunologic deficiency. Dis Chest. 1969;56:114–7. doi:10.1378/chest.56.2.114.
Woollons A, Darley CR. Yellow nail syndrome following Guillain–Barré syndrome. Clin Exp Dermatol. 1997;22:253–4. doi:10.1111/j.1365-2230.1997.tb01084.x.
Cockram CS, Richards P. Yellow nails and nephrotic syndrome. Br J Dermatol. 1979;101:707–9. doi:10.1111/j.1365-2133.1979.tb05651.x.
Sakiyama T, Shimizu T, Funakoshi T, Saito M. Case of yellow nail syndrome accompanied by nephrotic syndrome. J Dermatol. 2016;43:585–6. doi:10.1111/1346-8138.13239.
Dilley JJ, Kierland RR, Randall RV, Shick RM. Primary lymphedema associated with yellow nails and pleural effusions. JAMA. 1968;204:670–3. doi:10.1001/jama.1968.03140210024005.
Noël-Savina E, Paleiron N, Leroyer C, Descourt R. Découverte d'un syndrome des ongles jaunes lors d'une insuffisance thyroïdienne majeure. Rev Pneumol Clin. 2012;68:315–7. doi:10.1016/j.pneumo.2012.06.001.
Nakielna EM, Wilson J, Ballon HS. Yellow-nail syndrome: report of three cases. Can Med Assoc J. 1976;115:46–8.
Danenberg HD, Eliashar R, Flusser G, Rosenmann E, Chajek-Shaul T. Yellow nail syndrome and xanthogranulomatous pyelonephritis. Postgrad Med J. 1995;71:110–1.
David-Vaudey E, Jamard B, Hermant C, Cantagrel A. Yellow nail syndrome in rheumatoid arthritis: a drug-induced disease? Clin Rheumatol. 2004;23:376–8. doi:10.1007/s10067-004-0862-2.
Runyon BA, Forker EL, Sopko JA. Pleural-fluid kinetics in a patient with primary lymphedema, pleural effusions, and yellow nails. Am Rev Respir Dis. 1979;119:821–5.
Bokszczanin A, Levinson AI. Coexistent yellow nail syndrome and selective antibody deficiency. Ann Allergy Asthma Immunol. 2003;91:496–500. doi:10.1016/S1081-1206(10)61521-9.
Vignes S, Carcelain G. Increased surface receptor Fas (CD95) levels on CD4+ lymphocytes in patients with primary intestinal lymphangiectasia. Scand J Gastroenterol. 2009;44:252–6. doi:10.1080/00365520802321220.
Mattingly PC, Bossingham DH. Yellow nail syndrome in rheumatoid arthritis: report of three cases. Ann Rheum Dis. 1979;38:475–8.
Nakagomi D, Ikeda K, Kawashima H, Kobayashi Y, Suto A, Nakajima H. Bucillamine-induced yellow nail in Japanese patients with rheumatoid arthritis: two case reports and a review of 36 reported cases. Rheumatol Int. 2013;33:793–7. doi:10.1007/s00296-011-2241-z.
Mishra AK, George AA, George L. Yellow nail syndrome in rheumatoid arthritis: an aetiology beyond thiol drugs. Oxf Med Case Rep. 2016;2016:37–40. doi:10.1093/omcr/omw013.
Chiriac A, Brzezinski P, Foia L, Marincu I. Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons. Clin Interv Aging. 2015;10:265–7. doi:10.2147/CIA.S75525.
Haneke E. Isolated bullous lichen planus of the nails mimicking yellow nail syndrome. Clin Exp Dermatol. 1983;8:425–8. doi:10.1111/j.1365-2230.1983.tb01806.x.
Baran R. Lichen planus of the nails mimicking the yellow nail syndrome. Br J Dermatol. 2000;143:1117–8. doi:10.1046/j.1365-2133.2000.03811.x.
Tosti A, Piraccini BM, Cameli N. Nail changes in lichen planus may resemble those of yellow nail syndrome. Br J Dermatol. 2000;142:848–9. doi:10.1046/j.1365-2133.2000.03460.x.
Baran R, Rycroft RJG. Occupational abnormalities and contact dermatitis. In: Baran R, de Berker DAR, Holzberg M, Thomas L, editors. Baran and Dawber's diseases of the nails and their management. 4th ed. Oxford: Wiley-Blackwell; 2012. p. 443–69.
Jiyad Z, Cousins E, Stanton A, Mortimer P. Yellow nail syndrome: a primary lymphatic disorder? Br J Dermatol. 2014;171 Suppl 1:9. doi:10.1111/bjd.12930.
Abell E, Samman PD. Yellow nail syndrome treated by intra-lesional triamcinolone acetonide. Br J Dermatol. 1973;88:200–1.
Ayres Jr S, Mihan R. Yellow nail syndrome: response to vitamin E. Arch Dermatol. 1973;108:267–8. doi:10.1001/archderm.1973.01620230063024.
Williams HC, Buffham R, du Vivier A. Successful use of topical vitamin E solution in the treatment of nail changes in yellow nail syndrome. Arch Dermatol. 1991;127:1023–8. doi:10.1001/archderm.1991.01680060097012.
Arroyo JF, Cohen ML. Improvement of yellow nail syndrome with oral zinc supplementation. Clin Exp Dermatol. 1993;18:62–4. doi:10.1111/j.1365-2230.1993.tb00971.x.
Tosti A, Piraccini BM, Iorizzo M. Systemic itraconazole in the yellow nail syndrome. Br J Dermatol. 2002;146:1064–7. doi:10.1046/j.1365-2133.2002.04671.x.
Baran R, Thomas L. Combination of fluconazole and alpha-tocopherol in the treatment of yellow nail syndrome. J Drugs Dermatol. 2009;8:276–8.
Doncker PD, Pierard GE. Acquired nail beading in patients receiving itraconazole – an indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol. 1994;19:404–6. doi:10.1111/j.1365-2230.1994.tb02693.x.
Luyten C, André J, Walraevens C, De Doncker P. Yellow nail syndrome and onychomycosis. Experience with itraconazole pulse therapy combined with vitamin E. Dermatology. 1996;192:406–8.
Suzuki M, Yoshizawa A, Sugiyama H, Ichimura Y, Morita A, Takasaki J, et al. A case of yellow nail syndrome with dramatically improved nail discoloration by oral clarithromycin. Case Rep Dermatol. 2011;3:251–8. doi:10.1159/000334734.
Imadojemu S, Rubin A. Dramatic improvement of yellow nail syndrome with a combination of intralesional triamcinolone, fluconazole, and sinusitis management. Int J Dermatol. 2015;54:e497–9. doi:10.1111/ijd.12916.
Balmforth D, Bille A, Okiror L, Harrsion-Phipps K, Routledge T. Recurrent pleural effusion in yellow nail syndrome successfully treated with video-assisted thoracic surgery: comparison of two surgical strategies in two cases. Gen Thorac Cardiovasc Surg. 2013;61:231–3. doi:10.1007/s11748-012-0125-0.
Yamagishi T, Hatanaka N, Kamemura H, Nakazawa I, Hirano Y, Kodaka N, et al. Idiopathic yellow nail syndrome successfully treated with OK-432. Intern Med. 2007;46:1127–30. doi:10.2169/internalmedicine.46.0022.
Widjaja A, Gratz KF, Ockenga J, Wagner S, Manns MP. Octreotide for therapy of chylous ascites in yellow nail syndrome. Gastroenterology. 1999;116:1017–8.
Makrilakis K, Pavlatos S, Giannikopoulos G, Toubanakis C, Katsilambros N. Successful octreotide treatment of chylous pleural effusion and lymphedema in the yellow nail syndrome. Ann Intern Med. 2004;141:246–7. doi:10.7326/0003-4819-141-3-200408030-00027.
Lotfollahi L, Abedini A, Alavi Darazam I, Kiani A, Fadaii A. Yellow nail syndrome: report of a case successfully treated with octreotide. Tanaffos. 2015;14:67–71.
Hillerdal G. Yellow nail syndrome: treatment with octreotide. Clin Respir J. 2007;1:120–1. doi:10.1111/j.1752-699X.2007.00022.x.
Nakabayashi H, Sagara H, Usukura N, Yoshimitsu K, Imamura T, Seta T. Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs. Diabetes. 1981;30:440–5. doi:10.2337/diab.30.5.440.
Wahid ST, Marbach P, Stolz B, Miller M, James RA, Ball SG. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol. 2002;146:295–302. doi:10.1530/eje.0.1460295.
Cheville AL, McGarvey CL, Petrek JA, Russo SA, Taylor ME, Thiadens SR. Lymphedema management. Semin Radiat Oncol. 2003;13:290–301. doi:10.1016/S1053-4296(03)00035-3.
Lasinski BB, McKillip Thrift K, Squire D, Austin MK, Smith KM, Wanchai A, et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R. 2012;4:580–601. doi:10.1016/j.pmrj.2012.05.003.
International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 consensus document of the International Society of Lymphology. Lymphology. 2013;46:1–11.
Vignes S, Arrault M. Prise en charge des patients atteints de lymphœdème. In: Simon D, Traynard PY, Bourdillon F, Gagnayre R, Grimaldi A, editors. Education Thérapeutique. Paris: Elsevier Masson; 2013. p. 261–70.
DeCastro A, Mims L, Hueston WJ. Rhinosinusitis. Prim Care. 2014;41:47–61. doi:10.1016/j.pop.2013.10.006.
Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314:926–39. doi:10.1001/jama.2015.7544.
Khalil HS, Nunez DA. Functional endoscopic sinus surgery for chronic rhinosinusitis. Cochrane Database Syst Rev. 2006;3:CD004458. doi:10.1002/14651858.CD004458.pub2.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
SV conceived, designed and wrote the review, RB wrote the review. Both authors read and approved the final manuscript.
Department of Lymphology, Centre National de Référence des Maladies Vasculaires Rares (Lymphœdèmes primaires), Hôpital Cognacq-Jay, 15, rue Eugène-Millon, 75015, Paris, France
Stéphane Vignes
Nail Disease Centre, 42, rue des Serbes, 06400, Cannes, France
Robert Baran
Correspondence to Stéphane Vignes.
Vignes, S., Baran, R. Yellow nail syndrome: a review. Orphanet J Rare Dis 12, 42 (2017). https://doi.org/10.1186/s13023-017-0594-4
Respiratory manifestations
Rare skin diseases


The Intel Hardware Accelerated Execution Manager (Intel® HAXM) is a hardware-assisted virtualization engine (hypervisor) that uses Intel Virtualization Technology (VT) to speed up Android app emulation on a host machine. In combination with Android x86 emulator images provided by Intel and the official Android SDK Manager, HAXM allows for faster Android emulation on Intel VT enabled systems. HAXM for both Windows and OS X are available now.
Since Google mainly supports Android build on Linux platform (with Ubuntu 64-bit OS as top Linux platform, and OS X as 2nd), and a lot of Android Developers are using AVD on Eclipse or Android Studio hosted by a Linux system, it is very critical that Android developers take advantage of Intel hardware-assisted KVM virtualization for Linux just like HAXM for Windows and OS X.
Below are the quick step-by-step's on how to install, enable KVM on Ubuntu host platform and start Intel Android x86 emulator with Intel hardware-assisted virtualization (hypervisor). The result is very pleasing and AVD runs significantly faster and smoother than without hypervisor.
If the output is 0 it means that your CPU doesn't support hardware virtualization.
KVM acceleration can be used"
It means you can run your virtual machine faster with the KVM extensions.
KVM acceleration can NOT be used"
You need to go to BIOS setup and enable the VT.
Running a 64bit kernel on the host operating system is recommended since Google no longer offers support for 32bit kernel..
This allows the serving of more than 2GB of RAM for your VMs.
Also, a 64-bit system can host both 32-bit and 64-bit guests. A 32-bit system can only host 32-bit guests.
If 0 is printed, it means that your CPU is not 64-bit.
If 1 or higher, it is. Note: lm stands for Long Mode which equates to a 64-bit CPU.
x86_64 indicates a running 64-bit kernel. If you see i386, i486, i586 or i686, you're running a 32-bit kernel.
If it is displayed, you may ignore the Postfix Configuration below by selecting "No Configuration"
After the installation, you need to relogin so that your user account becomes an effective member of kvm and libvirtd user groups. The members of this group can run virtual machines.
Please referred to the instructions from Ubuntu community documentation page to get Java installed. There are four implementations of Java. Oracle java 7 has to be installed in order to run Android emulator x86 system Images.
Documented information on how to install Android sdk or Android Sudio can be found on android developers website.
Only a 64-bits Ubuntu can allow you to run allocated Memory of 2G or more. My 64-bit Ubuntu has 6G of Memory, so I used 1/3 of it for Android AVD. My AVD name is Intel_Atom_x86_64. '-qemu' provides the options to qemu, and '-m' specifies the amount of memory for the emulated Android (i.e. guest). If you use too small value for that, it's possible that performance is bad because of frequent swapping activities. Add '-show-kernel' to see the message from the kernel.
Run your Android project using this run configuration.
E: Package ia32-libs-multiarch cannot be found.
Please update the instructions, or, even better: Contact Google / IntelliJ to make the HAXM installation as simple as for Windows users (i.e. make it integrated into Android SDK Manager).
Where "..." is the path of your android sdk.
Now it works. It seems the local libqxcb.so android sdk library is incomplete.
emulator: WARNING: Classic qemu does not support SMP. The hw.cpu.ncore option from your config file is ignored.
"This application failed to start because it could not find or load the Qt platform plugin "xcb".
ı got error, when ı use <SDK directory>/tools/emulator-x86 -avd Your_AVD_Name -qemu -m 2047 -enable-kvm command.
emulator: ERROR: This AVD's configuration is missing a kernel file!!
Nexus_API_17 is a working emulator so I'm not sure what the problem is here. Any ideas?
Is there a way to verify from the log output that the emulator is running in accelerated mode once it's been set up? I set it up, ran the emulator, then I searched the log for 'kvm' and 'accel' but found nothing.
Where does "Your_AVD_Name" come from?


text:
Roger Legeay (Beaufay, 8 d'agost de 1949) va ser un ciclista i posteriorment director esportiu francès. Com a corredor fou professional entre 1973 i 1982. Un cop retirat es va dedicar a la direcció esportiva destacant el Gan, més tard anomenat Crédit agricole.

Palmarès
 1972
 Vencedor d'una etapa a la Ruta de França
 1978
 1r al Gran Premi de la costa normanda
 Vencedor d'una etapa al Tour de Romandia
 Vencedor d'una etapa al Circuit de la Sarthe
 Vencedor d'una etapa al Tour del Llemosí
 1980
 1r al Gran Premi de Mauléon-Moulins
 Vencedor d'una etapa al Circuit de la Sarthe
 1981
 1r al Gran Premi de Mauléon-Moulins

Resultats a la Volta a Espanya
 1974. 32è de la classificació general

Resultats al Tour de França
 1975. 71è de la classificació general
 1976. 35è de la classificació general
 1977. 37è de la classificació general
 1978. 42è de la classificació general
 1979. 63è de la classificació general
 1980. 84è de la classificació general
 1981. 61è de la classificació general

Resultats al Giro d'Itàlia
 1979. 62è de la classificació general

Referències
 Fitxa a sitiodeciclismo.net
 Fitxa a cyclebase.nl
 Fitxa a museociclismo.it

Ciclistes del País del Loira
Persones del Sarthe

redpajama_set_name: RedPajamaWikipedia


Mare Island Drawbridge Lift Bridge, originally uploaded by dmzajac2004-.
An unplanned photo op. While on the way to meet a Night Photography group to shoot with I wondered if the moon would line up over one of the Drawbridge towers and with a little scouting my friend Dali and I found a spot.
This bridge operates 16 hours a day, and is the first bridge you encounter on the Northwest Passage up the Napa River.


1) Our hourly schedule is live and up to date using the link below. If the schedule changes, it'll change here too.
2) When you view the calendar link, click on the banner for that day and a box will open with the housing location.
3) When you view the calendar link, the daily schedule will show our performance time. Or you can also click on the banner for that day and see the entire show schedule.
4) The following link is an interactive & graphic layout of our 2013 summer tour. When you click on the push pin for the show you want, you can get to that show's website by clicking on the City, State. From there, you can find out how to get tickets to that show.
The weather on the front page of regiment.org will show the weather for the current show or rehearsal location for that day. So you can follow along with us and know if we're outside rehearsing or inside waiting for a storm to pass.
Also, don't forget mail stops! Everyone loves receiving mail from home while on the road.


DRG, Designer-Reading-Glasses.com proudly offers Designer Eyeglass frames from top brands such as: Ray Ban, Prada, Versace, Tag Heuer, Persol, Porsche, Ferrari, Salvatire Ferragamo,, Porsche, Tommy Bahama, Matsuda, Ink, Lucky Brand, and many more. These are the same high quality frames sold in optical stores for several times our price. We then custom make prescription reading glass lenses to order in powers from +0.25 up to +4.00. You can now have a unique custom prescription reading glass made for you, for the same price as a boutique reading glass.


text:
BOGO Deals
The Redneck Comedy Bus Tour
Johnny Cash Museum
Nashville Old Town Trolley Tour
Ryman Auditorium Tours
Country Music Hall of Fame and Museum
La Quinta Inn & Suites North Nashville
Best Western Suites Near Opryland
Holiday Inn Express & Suites Opryland
Gaylord Opryland Hotel
VACATIONS MADE EASY : DESTINATIONS : TN : NASHVILLE : ARTICLES
Nashville Christmas Village Shopping Information
It's beginning to look a lot like Christmas at the Tennessee State Fairgrounds in Nashville with all of the lights, merriment, and cheer! From November 12 -14, merchants from all over the United States will be coming together to set up the 44th annual Nashville Christmas Village. Just a short distance from downtown Nashville, Christmas Village is fun, convenient, exciting and unique. If you love everything about the holiday season, this amazing shopping experience is the place to be!
Called a shopper's dream, Christmas Village consists of more than 260 merchants of all different kinds, selling just about everything you could think of! It takes several buildings on the site just to accommodate all of them. Do you have an uncle who loves pewter gifts or a sister who just has to have personalized hand towels for Christmas? And what about all those people on Santa's list who seem to have everything? Well, instead of driving through a maze of crazy holiday traffic to get to shops all over town, why not come to The Christmas Village, where you'll find every gift you need for this holiday season, all in one convenient location! Since the Village contains all Christmas and gift-themed items, you can find decorations, home furnishings, crafts, art, handmade items, jewelry, apparel, toys, children's gifts, cookbooks, food and much more. You will find remarkable, original and one-of-a-kind items, perfect for surprising everyone on your Christmas list.
Christmas Village, which began in 1961, is a yearly event put together by the Nashville Pi Beta Phi Alumnae Club. Ticket sales go to benefit the philanthropies of this group, including the Vanderbilt Bill Wilkerson Center, the Arrowmont School of Arts and Crafts and others. Last year, more than 20,000 people came to Christmas Village, experienced Nashville's most prestigious consumer show, and supported these programs.
It's an amazingly creative and fun way to get talented artists and retailers together to showcase and sell unique gifts, gorgeous holiday decorations, delicious food and everything else you need for a Christmas to remember! Plus, it's a great way to support some worthy causes. Christmas Village is open from 9:00 a.m. to 6 p.m. on November 12 and 13, and noon to 6:00 p.m. on November 14. You pay just one fee to have access to all the buildings, and children nine and under are free! Once you've experienced it, you will know why it has been called the premier consumer show in the southeast.
After a long and successful day of shopping, you will want to retire somewhere close by that offers a relaxing atmosphere. Nearby accommodations include:
View By Date:
January February March April May June July August September October November December 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Length of Visit:
1 Day 2 Days 3 Days 4 Days


Contact Trinity in Japan Society. All contacts are welcome. Trinity in Japan is an officially recognized group of Trinity College Cambridge. We meet regularly in Tokyo and other places in Japan for discussions and other events. All Fellows, members, alumni of Trinity College Cambridge are welcome to join us.


text:
Q: Android Realm migration issue: Can an older version of an app get stuck with the data files of a newer version? When an Android app is updated using the package manager API is it possible for it to get into a state where the app has data files from the newer version of the app yet the older version of the app is still installed and running on the phone?
I'm diagnosing an Android app on a handset returned from a customer that was developed using Realm 1.0.0 database. It appears the app failed to update to a newer version of our software for some reason. The newer version of the app had a schema v4. The older version of the app had schema v3. We don't use the Play Store for distributing upgrades. We have our own web servers where the app downloads APK file upgrades of itself which are then installed by invoking the Package Manager with the following intent:
Intent intent = new Intent(Intent.ACTION_VIEW);
intent.setDataAndType(Uri.fromFile(file), "application/vnd.android.package-archive");
startActivity(intent);

When the app starts it crashes with the following error:

Realm on disc is newer then the one specified. V4 vs V3.

If I look in Settings > Apps I can see the app installed is the older version using V3 of our schema. Yet the .realm file the app is loading from internal storage has a v4 schema belonging to the newer version of our app.
The app runs on a Moto E2 phone running Lollipop 5.0.2.

A: It sounds like some user downgraded your app most likely?
Realm doesn't have support for downgrading Realm files automatically. If you wish to allow downgrades, you need to still bump the schema version to the next level : 4 -> 5, and specify the migration there as the inverse of 3 - > 4.
Given your scenario that sounds impossible, since I assume a user can downgrade to any previous version?
In that case you have two choices:
1) Detect that a downgrade has happened by catching that exception and show a warning to the user that they cannot downgrade.
2) Detect that a downgrade has happened and delete the Realm file.

redpajama_set_name: RedPajamaStackExchange


A parent doesn't have to be human to be a great Dad to their kids.
They leave us their legacy, their DNA.
Without Dads, life could not be created. We wouldn't exist.
We need to protect Dad's of ALL species – yep, they're that important.


text:
Q: Variable not accessible after thread start() method So this is my code for the class that implements Runnable.
public class SeedDownload implements Runnable {

    private StringBuilder htmlSB;
    private String bingSeed;

    public SeedDownload(StringBuilder string) {
        htmlSB = string;
    }

    public void run() {
        Pattern pattern = Pattern.compile("class=\"b_algo\">
<a href=\"(.+?)\" h=\"");
        Matcher matcher = pattern.matcher(htmlSB);

        if (matcher.find()) {
            bingSeed = matcher.group(1);
            System.out.println(bingSeed);
        }
    } //End of run

    public String getUrlLink() {
        return bingSeed;
    }

}

And this is the code in my main class.
StringBuilder htmlResult = PageRead.readPage(String.format("https://bing.com/search?q=%s", query));
     System.out.println(htmlResult);
    SeedDownload sdBing = new SeedDownload(htmlResult);
    Thread bingThread = new Thread(sdBing);
    bingThread.start();

    System.out.println(sdBing.getUrlLink());

And this is the output when ran.
"    null

https://en.wikipedia.org/wiki/Hello_world_program "

Apparently, the print in the run method could access the the variable, whereas in the main class, it couldn't. Is it something to do with the run() method being stopped and the contents of it not being accessible?

A: You just have a volatilness issue, the getter is not retrieving the updated value of the string, so your string object must be volatile! so you can be sure that you get the updated value when you call the getter
change this
private String bingSeed;

with
private volatile String bingSeed;

from oracle doc:

Using volatile variables reduces the risk of memory consistency
  errors, because any write to a volatile variable establishes a
  happens-before relationship with subsequent reads of that same
  variable. This means that changes to a volatile variable are always
  visible to other threads. What's more, it also means that when a
  thread reads a volatile variable, it sees not just the latest change
  to the volatile, but also the side effects of the code that led up the
  change.

A: It's not that it is not accessible, but because the modification of the variable bingSeed happens in another thread than the main thread, the System.out.println() of the main thread executes WHEN the bingSeed is still null
you have options here, either wait for the thread to finish using synchronisation or submit the thread to an Executors Service and poll the result

A: You have two main problems
When you are running
 bingThread.start();
 System.out.println(sdBing.getUrlLink());

you are assuming that the Thread has started and has already assigned a value to bingSeed - this maybe not the case, so before calling getUrlLink ensure that the Thread has finished by adding
bingThread.join();

Secondly, to ensure that the most-up-to-date value of bingSeed is being used make it volatile as in
private volatile String bingSeed;

A: The thread is producing its result independently, performing asynchronous or background processing.So the thread will produce the result independently, but the java program may have gone far already, after its request to this thread.So no result is got to the java program,but the result is given by thread correctly.This is why it is null. Use volatile keyword for this.

A: In your code there are two possiblities of getting null value i.e
1) matcher.find() gives false result in that case you will get a non
   initialized value i.e null.
2) your print statement is executing before your thread is assigning value
   to bingSeed
you can check this by providing true value to if block of matcher.find()
in this case you will get null value if matcher doesnt have any match.
Also, for 2nd point you can sleep your thread to wait and let the bingSeed initialize.
     `bingThread.start();
     Thread.sleep(millis);  // it will halt your main thread and you will get your variable value.
     System.out.println(sdBing.getUrlLink());`

i tried it and it worked fine after these checks


Yesterday the internet was broke, again. Odd, since the last time it broke was the day after an internet chum's birfday (leeg's) and a night of fun gaming. The day before yesterday was another internet chum's birfday (mizan's)....so, quite the strange coincidence...that's probably not worth mentioning but I did anyway.
Bleh.. uber-depressed, even though the internet is back.
This is me, flipping off who ever is responsible for this stuff.


text:
Lab Research
Meet The Lab
Dr. Ramsey D. Badawi
Dr. Rosalie Hagge
Dr. Ramsey Badawi
Ramsey D. Badawi
Director of Research,
Division of Nuclear Medicine
Associate Professor of Biomedical Engineering
Ph.D. (Biophysics), University of London, UK
M.Sc. (Astronomy) and
B.Sc.(Physics), University of Sussex, UK
Email: ramsey.badawi@ucdmc.ucdavis.edu
Abhijit Chaudhari
Assistant Professor of Radiology
Ph.D. (Electrical Engineering) and M.S. (Applied Mathematics), University of Southern California, USA
M.S. (Electrical Engineering) California State University, Northridge, CA, USA
B.S. (Electronics Engineering), University of Pune, India.
Email: ajchaudhari@ucdavis.edu
Rosalie Hagge
M.D. Washington University St Louis, MO
M.S. (Computer Science), Washington University, St Louis, MO
B.S. (Computer Science), Washington University, St Louis, MO
Email: Rosalie.Hagge@ucdmc.ucdavis.edu
Seema Prasad
Email: seema.prasad@ucdmc.ucdavis.edu
Shruti Agarwal
Ph.D. (Applied Mathematics) Indian Institute of Technology Kanpur, India,
M.Sc. & B.Sc. (Mathematics) University of Rajasthan, India
Email: shagarwal@ucdavis.edu
Andrea Ferrero
Graduate Student (Ph.D.)
Email: Aferrero@ucdavis.edu
Felipe Godinez
Email: fgodinez@ucdavis.edu
Jonathan Poon
Graduate student(Ph.D.)
Email: jkpoon@ucdavis.edu
Jonathan Santos
Undergraduate student (B.S.)
Email : jonsantos@ucdavis.edu
Holly Marciniak Thompson,
MD, MPH Diagnostic Radiology Resident, R2
Graduates and former lab members
Quan Zeng (2008-2012)
Sara St. James Ph.D (2011)
John Zimmerman Ph.D (2009-2010)
Tracy Brown (2009-2011)
Jessica Saiz, M.S. (2008-2011)
Prof. Dr. Eder Rezende Moraes Ph.D. (2010)
Meena Kumar, M.D. (2008-2011)
Spencer Bowen, Ph.D.(2005-2010)
Jinxiu Cheng-Liao, Ph.D.(2009-2010)
Phil Granchi, M.D. (2009-2011)
Isaac Kim (2008-2009)
Fang Yuan, Ph.D.(2008-2009)
Shrabani Sinha, Ph.D.(2008)
Frank Lin (2007-2009)
Huini Du, Ph.D. (2008-2009)
Linus Ong, B.S.(2007-2008)
Shonket Ray, M.S.(2005-2008)
Jennifer Stickel, Ph.D.(2006-2007)
Susan Tanner (2008)
Jerry Wu, M.S. (2007)
MOLECULAR AND TRANSLATIONAL IMAGING LABORATORY | Powered by Mantra & WordPress.
Privacy and Accessibility UC Davis Principles of Community


Whenever I make this bowl and snap a pic for Insta Stories, I get tons of requests for the recipe. Now that it's here, we all have a spot to reference and it's easier than trying to explain it over DM lol (ps – I love seeing your pics when you make this!). I discovered this combo when we were doing Whole30 & I've been addicted ever since. If I could eat one thing for the rest of my life it would probably be this bowl. Every. Day. It's Whole30 compliant as is, but you could also add brown rice (I have, it's so good), cauliflower rice, onions, or any other veggies you love. I keep it simple most days with only 3 ingredients – egg, sweet potato, avocado. See the recipe below, enjoy! My dishes are here – another FAQ when I post this ;).
*I don't measure the seasonings, I just load them on (don't be shy with it). Also you can add or take out any seasonings – just include what you like.
5. Uncover, continue to cook sweet potato so the sides get a little brown/crispy.
6. In the same pan, add the egg and cook to preference. *For this recipe, the runny yolk is key IMO. I cook mine over easy/medium (I'm no egg expert, so basically I spend this time trying to cook the whites without breaking the yolk).
7. Once egg is done, combine sweet potato + egg in a bowl and top with avocado and red pepper flakes.
8. Try not to eat the whole bowl in 37 seconds.
yummy! I'm trying this tonight!
Currently obsessed with this recipe! I've also been putting it on top of a mix of power greens and arugula from Trader Joe's . SO yummy!


It's more than sophisticated and even more than extraordinarily chic. The amazing Rachel Roy fall/winter 2014-2015 collection showcased at New York Fashion Week is already available for our in-detail scrutiny offering a very interesting array of options from curious experiments and catchy shapes to flabbergasting color interpretations and memorable details. "I designed what I wanted and needed and what I thought would work,' said Rachel Roy about her collection.
All about the spectacular and breathtaking garments can be found here in the Rachel Roy fall/winter 2014-2015 collection, put with the most impressive stylish mishmashes and combos possible. Thus, the looks start with an amazing navy blue dress having some very scrupulous design patterns of black glittery details, and a very catchy transparency for the bottom part. The bluish gloves and the stiletto heels complement this look ideally.
Following the array of the options in blue we also see the timeless combination of the blue and grey, used for the combination of the straight skirt, the bluish top and the matching greyish jacket with cuffed sleeves. For the all red looks, we have the amazing trio of the skirt, top, and jacket again, which again has the spectacular transparency plays and the overall feminine outlines with it.
The furry with floral combinations are also impressive composing the most luxurious part of the Rachel Roy fall/winter 2014-2015 collection. The color diversities of these options are also various ranging from red and blue to purple. Talking about the latter, we can't but also note the flabbergasting compositions involving leather jackets, thus introducing the mishmash of sporty and classic.
Finally, it's the black apparels that finish up this line, securing the glamorous and mysterious aspect of the Rachel Roy fall/winter 2014-2015 collection. Thus, here we had one of the most amazing collections for the fall/winter season, which, in case of opting for the amazing pieces of the Rachel Roy fall/winter 2014-2015 collection will be ultra-striking and unforgettable.


text:
Skydivers perform a record breaking display i
Ottawa: A new world record for the largest ever clomid for increased ejaculate vertical skydiving has been created in Ottawa, Illinois. 164 skydivers achieved this remarkable feat by traveling at a speed of up to 240 mph. They performed the enchanting show by flying head-down just before building the largest ever vertical skydiving formation overcoming the previous rec...
Brazillica 2015 celebrates in Liverpool
Liverpool (UK): The increasingly popular Brazillica festival is being celebrated in England from July 17th to July 19th. This is the eighth consecutive year that the festival is being celebrated. The organizers Liverpool carnival company has showcased their best efforts to to cover the streets with spectacular Brazilian colors and lights. There were numerous colorful cultural events which could highlight the sights, sounds and tastes of Brazil. This time the organizers were well planned not to d...
Amazing tricks of unicyclist Brian Kidd
United States: Unicyclist Brian Kidd is also known as the Unipiper as he uses his flame throwing bagpipes to deliver a classical score while balancing on an Unicycle. Thus Brian Kidd combined two unusual hobbies to create an extraordinary entertainment. He has performed this feat in a variety of costumes including that of Darth Vader, Santa Claus, and Gandalf. While performing according to the costumes he also tries to deliver character-appropriate tunes on the pipes. Nowadays, he is famous i...
Michelle Obama once again Dances with Jimmy F
Washington: Michelle Obama once again proved her coolest nature as the First Lady of USA. Her recent coolest appearance was when she 'lotus danced' with comedian TV host Jimmy Fallon in April 2015. Her previous coolest appearance was when she mom danced with Jimmy Fallon in February 2013. Earlier, during so many occasions, Michelle Obama has exhibited her talent and interest in dancing The spectacular dancing was during the five year anniversary celebrations of the movement, 'Let's Move'. T...
TEMPLE RUN ANDROID
Temple run is the recently launched android game which is very interesting. This can be played with the help of widely prevalent android devices like I-phone, I-pad etc. This is a good entertainer which invaded the minds of android game lovers. It is really amazing that the game has got warm welcome worldwide within a few days after its introduction on January 17th 2013. The player can fully rely on the unique characteristic features of the game which are generally known as options...


Posted on January 21, 2019 .
Join Chairwoman of the Orange County Board of Supervisors Lisa Bartlett and the Orange County Children's Partnership on Friday, February 15, 2019 for a community forum on the 24th Annual Report on the Conditions of Children in Orange County.
The forum will include an overview of key indicators of Orange County children's well-being and speakers on the topic of children's mental health.
All attendees will receive a free copy of the Conditions of Children Report.


Saturday is hockey day every week. While I'll be locked in on the Hurricanes against Virginia Tech tonight, I'll be channel flipping with the Rangers at Panthers along with other fun match-ups on Hockey Night In Canada and Center Ice.
There's something for everyone. Even if your team is idle like the Islanders and the Devils, who were victimized by Connor McDavid (3 assists) last night in a 6-3 loss to the Oilers. On Daylight Savings time with us getting ab extra hour back when the clock strikes 2 AM on the even of the New York City Marathon, there'll be plenty of action. Good luck to my buddy Patrick tomorrow as he starts in Fort Wadsworth out in Staten Island crossing the Verrazano Bridge and runs his first NYC Marathon. Ironically, it was my father who ran it in 1980 when I was little.
One game has already been played with the Vegas Golden Knights snapping a three-game losing streak by going into Ottawa and defeating the Senators 5-4. Jonathan Marchessault and Erik Haula each recorded three points and Alex Tuch scored in support of Maxime Lagace, who won his first game with 24 saves. Derick Brassard had two assists in the third period but Ottawa's rally fell short.
Good by Sportsnet having Nicholle Anderson on between the second and third period to talk about her winning battle with cancer. It was interesting hearing the wife of Ottawa goalie Craig Anderson talk about how she revealed to her husband that she was cancer free in the playoffs. She now is the 2017 NHL Ambassador for #HockeyFightsCancer initiative. She joined 10-year old Ryan at center ice for an emotional ceremonial puck drop with the Knights' David Perron and Ottawa captain Erik Karlsson. First class.
On Friday night, it was Brian Boyle joining Connor McDavid. Boyle has just returned from his battle with leukemia. He played his second game after debuting for the Devils at Vancouver.
In related news, former referee Kerry Fraser revealed that he is battling incurable leukemia. What a sad thing for the likable 65-Year old. Fraser is a class guy who is extremely popular in the hockey community. The man with the cool hair and similar look to actor William H. Macy has always been nice. I can recall him saying hello to me when I was a production assistant for the Devils in '00-01. I was just a kid out of college. That's the kind of great person he is. I am deeply saddened by this news. That's why we must do whatever we can to fight this awful disease.
We'll see if they're up to the challenge. They just came off the best win of the season. A well earned 2-1 overtime victory over Tampa with J.T. Miller scoring the exciting OT winner on a brilliant rush.
The Panthers aren't the Lightning with just four wins so far. They're not good defensively and have suspect goaltending without Roberto Luongo. James Reimer is finding life harder as the starter with Luongo out. He was chased the other night by Columbus in a 7-3 loss which followed a 8-5 defeat to the Bolts. That's a whopping 15 goals allowed in two straight. If I were the Blueshirts, I would be on high alert.
UPDATE: Luongo is back and starting. So it could be a boost for Florida. My mistake.
Florida can score. Aleksander Barkov is their best player. He has all the tools to be a superstar combining superb skating with good playmaking and finishing ability. He's got 14 points (6-8-14) which ties him with Jonathan Huberdeau, Evgenii Dadonov and always dangerous two-way threat Vincent Trocheck. Radim Vrbata remains a streaky finisher getting all three in one game. He is a good right shot on the power play. Nick Bjugstad isn't scoring and the Cats' depth isn't great.
The Rangers must account for offensive D Aaron Ekblad (3-4-7) and Keith Yandle (1-5-6). They are like extra forwards on the attack who can hurt you if they're not covered. It would be wise to avoid penalties.
There's one lineup change due to rookie Boo Nieves having the flu. Paul Carey is in on the fourth line with Michael Grabner and Jesper Fast while the benched David Desharnais centers Miller and Jimmy Vesey. Brendan Smith sits out a second straight (4th healthy scratch) in favor of Steven Kampfer with Nick Holden staying in with Ryan McDonagh. Smith better get his act together or that four-year contract will be one of the worst signings by Jeff Gorton.
Last thing. Don't get into a run and gun with the fast skating Panthers. It tends to favor them. The Rangers should remain smart in decision making and take advantage of Panther mistakes. Establish the forecheck and score early. Henrik Lundqvist gets his third straight start.
A couple of other early games feature Columbus and Tampa while the struggling Leafs visit the West's best in St. Louis. Montreal is at surprising Winnipeg. The Sabres go for two straight at Dallas. We'll see if Evander Kane and Jack Eichel can stay hot. In late action, the Sharks and Ducks hook up in one of the best Western rivalries. Expect fireworks.


Driving in December means more chance of being involved in a vehicle accident, and it may be one that is fatal. This increased risk of accidents will also likely result in the need for many individuals to seek the help of an auto accident lawyer.
It's December, and the roads are filled with anxious shoppers on the hunt for the next deal, and friends and family making the trek to see others for the holidays. There are more holiday parties and Christmas revelers, which means that there is an increased chance of drivers under the influence on the roads, and there are more distractions, which means that drivers aren't always focused on what's on the road in front them.
According to the Oregon State Police, there were 25 auto accidents in Oregon that resulted in the death of an individual involved. Nearly a third of these accidents involved drivers who were under the influence of drugs or alcohol. Two of the fatal accidents actually occurred in the three-day period surrounding Christmas, and both involved impaired drivers. These are scary statistics to consider, especially when for many families, this time of year is supposed to be one of joy, charity, and togetherness. The last thing that anyone wants to deal with at any time, but especially during the holidays, is the loss of a loved one due to the negligence or misconduct of an impaired driver.
Unfortunately, it appears that Oregon is on track to having another record year in terms of December accidents. For example, it was reported that on December 6th, an impaired driver struck an Oregon State Police car near Gold Beach on Highway 101. With accidents like these happening so early in the holiday season, Oregon law enforcement agencies have realized that it's time to take another approach.
This year, state agencies are taking a much stronger stance on the impaired driving issue in order to ensure that drivers remain safe on the roads and don't find themselves in need of an auto accident lawyer. This is why the Oregon Department of Transportation has joined a national campaign that was created in order to reduce the amount of fatalities, injuries, and crashes that may occurring during this time of year. Governor Kitzhaber has deemed December the Drunk and Drugged Driving Awareness Month, and is urging Oregon citizens to drive safely, plan ahead, and watch out for others.
To help you stay safe on the roads this holiday season, follow these important tips. Never drive at times when you are overly fatigued, and always make sure that you have had enough sleep when undertaking a long road trip. When you are on the road for long periods of time, be sure to get regular rest and take a refreshment break if you need it. Never drive while under the influence of drugs or alcohol. When you know you'll be drinking, make sure to make alternative transportation arrangements such as taking public transportation or having a designated driver. Always use your daytime running lights to help your visibility, and make sure to allow yourself enough space between you and the car in front you.


I would like to thank my takbo.ph family for the loving support which leads us to finish the 70 kilometer race that is PAU Ilocos Norte. I could never thank you enough guys! I love you all!
I would also like to thank Sir Jovie "Baldrunner" Narcise for coming up with wonderful races that really showcase not just Filipinos' talents but also the hidden beauty of the Philippines. This race is easily one of my most favorite races ever and I'm very much looking forward to the next! Congratulations Sir for a very successful event!
To the people of Ilocos Norte, thank you for your warm welcome and hospitality! I'll definitely be back!
Keep it up your advocacy! Hope to see you again in Ilocos.


Over the years, Business Point has accumulated substantial experience in property management. We understand how a company's goal and success can be supported and reinforced with the proper and well-rounded facilities paired with an experienced and knowledgeable staff team.
We understand that the cost of your industrial space can be the determining factor of your business location. That's why we're not only lower priced than the competition but we offer flexible leases and additional services to give your business an advantage over your own competition.
We understand that starting a new business or moving your current business can be a stressful and complicated endeavour; figuring out what sizes and configurations you would need, whether or not city zoning permits, ceiling heights and parking all come into consideration. Most, importantly, you just need something that works. From your first inquiry about industrial space to handing you the keys of your brand new unit and beyond, we are with you providing the help and advice you need along the way, so that you can focus on your business, not your business set-up.
Throughout your tenancy we are available in person, by phone and online to support your business every step of the way. Your online tenant's account has all the documentation you'll need so you can stop worrying about where your paper copies were filed or whether you've reached the right person with any concerns you may have.
We're a lot more than just commercial spaces. Our "Solid System" is built upon the tools that simplify and extend your business in the ways that others do not offer. From our Tenant Management Communication Portal to our Customer Relationship Marketing (CRM) tools we have the processes in place that will keep your business office running smoothly and your customer relationships happy and growing. A solid foundation to effectively help you manage and grow your business.